Background: We evaluated candidate circulating serum cytokines, chemokines and growth factors in patients with locally/regionally advanced melanoma receiving neoadjuvant ipilimumab with toxicity and clinical outcome.
Methods: Patients were treated with ipilimumab (10 mg/kg IV every 3 weeks, 2 doses) before and after surgery. xMAP multiplex serum testing for 36 functionally selected cytokines and chemokines was performed at baseline and at six weeks (following ipilimumab). Based on our prior data, the association of IL-17 and immune related colitis was tested. Serum cytokines were divided into functional groups (Th1, Th2, Regulatory, Proinflammatory) and were assessed at baseline and week 6 using sparse-group Lasso modeling to assess the association of various cytokine groups with progression free survival (PFS). The linear combination of the cytokines/chemokines in this model was then used as a risk score and a Kaplan-Meier curve was generated to examine the association of the dichotomized score and PFS.
Results: Thirty-five patients were enrolled whose staging was: IIIB (3; N2b), IIIC (30; N2c, N3), IV (2). Median follow-up was 18 months. Among 33 evaluable patients, median PFS was 11 months (95 % CI = 6.2-19.2). IL-17 was found to correlate significantly with the incidence of grade 3 diarrhea/colitis when measured at baseline (p = 0.02) with a trend towards significance at 6 weeks (p = 0.06). In the modeling analysis, at baseline, the linear combination of 2 regulatory cytokines [TGF- β1 (ρ = 0.19) and IL-10 (ρ = -0.34)] was significantly associated with PFS (HR 2.66; p = 0.035). No significant correlations with clinical outcomes were found in examining the week 6 cytokines.
Conclusions: Baseline IL-17 level was significantly associated with the later development of severe diarrhea/colitis while the combination of baseline TGF- β1 and IL-10 levels were associated with therapeutic clinical outcome after neoadjuvant ipilimumab. These findings warrant further investigation and validation.
Trial Registration: ClinicalTrials.gov Identifier NCT00972933.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570556 | PMC |
http://dx.doi.org/10.1186/s40425-015-0081-1 | DOI Listing |
Allergol Immunopathol (Madr)
January 2025
Department of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zheiiang, China.
To illustrate the potential of mesenchymal stem cell-derived exosomes (MSC-Exos) in mitigating septic lung injury by reducing the excessive formation of neutrophil extracellular traps (NETs), a mouse model of septic lung injury was induced through cecal ligation and puncture (CLP). The mice received intraperitoneal injections of MSC-Exos. Post injection, pathological alterations of the lung tissue were evaluated through HE staining, and the levels of inflammatory markers in each mouse group at various time points were assessed using ELISA kits.
View Article and Find Full Text PDFBackground: Alzheimer's and Parkinson's disease are the most common neurodegenerative diseases. In the current study, we explored the potential of blood-based markers to differentiate Alzheimer's disease (AD) and Parkinson's disease (PD) from healthy controls using ELISA assays via measuring the serum level of α-Syn and panels of inflammatory cytokines in the small pilot cohort of Egyptian volunteers. With the ongoing genetic studies, upcoming data suggest that it is not trivial to revisit the findings reported in specific populations to be tested in each ancestor of different genetic and environmental backgrounds.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, Cologne, North-rhine westphalia, Germany.
Background: Alzheimer's disease (AD) presents a prolonged asymptomatic phase, providing a significant timeframe for potential intervention. Leveraging this opportunity necessitates the early identification of diagnostic and prognostic biomarkers to detect Alzheimer's pathology during predementia stages. This enables the identification of individuals likely to progress to Alzheimer's-type dementia, allowing them to benefit from targeted disease-modifying therapies.
View Article and Find Full Text PDFBackground: Alzheimer's Disease (AD) has been associated with neurocognitive, metabolic, and neuroinflammatory alterations. Currently, there are no useful biomarkers in low-resource countries, and genetic risk/protection factors in Peruvians are unknown.
Objective: To establish the first serum bank in the northern part of the country for the analysis of participants with mild cognitive impairment (MCI) or AD.
Background: Early neuroinflammation is involved in pathophysiology of Alzheimer's Disease (AD) and contributes to faster clinical decline. Thus, neuroinflammation has emerged as a promising therapeutic target for dementia. However, a better understanding of the interaction between central and peripheral inflammation in human disease and in vivo biomarkers are required for successful clinical trials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!